Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03729115 · ClinicalTrials.gov registry record · NA

A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer

A NA study of Breast Cancer, sponsored by University of Chicago.

Recruiting
Registry status
NA
Development phase
400
Enrollment target
1
Study location

NCT03729115 is a NA study of Breast Cancer that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 400 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03729115, a NA study of Breast Cancer, is actively recruiting participants, sponsored by University of Chicago.

RECRUITING
Registry status
NA
Development phase
400 participants
Enrollment target
1
Study location

Study Summary

This study is aimed to establish a registry of women undergoing intensive surveillance for the early detection of breast cancer in high-risk women.

Conditions Studied

Interventions

  • PROCEDURE Magnetic Resonance Imaging (MRI)

Study Locations (1)

Illinois

  • University Of Chicago Medicine Comprehensive Cancer Center - Chicago

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2019-05-30
Est. Completion 2028-12-31
Phase NA

Sponsor

University of Chicago

796 total trials

What the Registry Record Tells You About NCT03729115

The ClinicalTrials.gov registry entry for NCT03729115 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (86% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Magnetic Resonance Imaging (MRI) is the first listed.

NCT03729115 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT03729115 about?

NCT03729115 is a clinical study titled "A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer". This study is aimed to establish a registry of women undergoing intensive surveillance for the early detection of breast cancer in high-risk women.

What is the current status of trial NCT03729115?

This trial is currently recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2019-05-30. Estimated completion is 2028-12-31.

What conditions does trial NCT03729115 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT03729115?

The interventions under investigation include: Magnetic Resonance Imaging (MRI) (PROCEDURE).

Who is sponsoring clinical trial NCT03729115?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03729115 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.